In a new note to investors today, an analyst has provided a rating update for Medexus Pharmaceuticals Inc (MDP – Research Report). The Healthcare company, Medexus Pharmaceuticals Inc (TSX: MDP) has just received a rating update from a Wall Street analyst.
According to TipRanks.com, Quenneville ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.5% and a 27.3% success rate. Quenneville covers the Healthcare sector, focusing on stocks such as Cognetivity Neurosciences, Antibe Therapeutics, and Valeo Pharma.
Currently, the analyst consensus on Medexus Pharmaceuticals Inc is a Strong Buy with an average price target of C$3.83.
The company has a one-year high of C$3.53 and a one-year low of C$1.12. Currently, Medexus Pharmaceuticals Inc has an average volume of 42.62K.
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
The company’s shares closed last Thursday at C$2.00.
